Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2201-2205

  Lin, Gengrong ^a   Pankuch, Glenn A ^a   Ednie, Lois M ^a   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; MEROPENEM; OXACILLIN; RIFAMPICIN; TELAVANCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; DRUG POTENTIATION; DRUG SCREENING; HOSPITAL INFECTION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEPHALOSPORINS; CIPROFLOXACIN; DRUG SYNERGISM; GENTAMICINS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXACILLIN; RIFAMPIN; THIENAMYCINS; TIME FACTORS;

EID: 77951221511     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01143-09     Document Type: Article

References (31)

1. Adern, P. V., C. P. Montgomery, A. N. Husain, T. K. Koogler, V. Arangelovich, M. Humilier, S. Boyle-Vavra, and R. S. Daum. 2005. Staphylococcus aureus sepsis and the Waterhouse-Freiderichsen syndrome in children. N. Engl. J. Med. 353:1245-1251.
2. American Society for Microbiology. 2010. Instructions to authors. Antimicrob. Agents Chemother. 54:1-23.
3. Boucher, H. W., G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg, and J. Bartlett. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
4. Clark, C. L., M. R. Jacobs, and P. C. Appelbaum. 1999. Activities of clinafloxacin, alone and in combination with other compounds, against 45 Gram-positive and -negative organisms for which clinafloxacin MICs are high. Antimicrob. Agents Chemother. 43:2295-2298.
5. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S19. Nine-teenth informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Credito, K., G. Lin, and P. C. Appelbaum. 2007. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob. Agents Chemother. 51:1504-1507.
7. Cui, L., A. Iwamoto, J. Q. Lian, H. M. Neoh, T. Murayama, Y. Horikawa, and K. Hiramatsu. 2006. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:428-438.
8. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
9. de Lassence, A., N. Hidri, J. F. Timsit, M.-L. Joly-Guillou, G. Thiery, A. Boyer, P. Lable, A. Blivet, H. Kalinowski, Y. Martin, J. P. Lajonchere, and D. Dreyfuss. 2006. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin. Infect. Dis. 42:170-178.
10. Denis, O., A. Deplano, H. de Beenhouwer, M. Hallin, G. Huysmans, M. G. Garrino, Y. Glupczynski, X. Malaviolle, A. Vergison, and M. J. Streulens. 2005. Polyclonal emergence and importation of community-acquired methicillin-resistant Staphylococcus aureus strains harbouring Panton-Valentine leukocidin genes in Belgium. J. Antimicrob. Chemother. 56:1103-1106.
11. Deresinski, S. 2005. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40:562-573.
12. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:2383-2388.
13. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62:116-121.
14. Fischbach, M. A., and C. T. Walsh. 2009. Antibiotics for emerging pathogens. Science 325:1089-1093.
15. Francis, J. S., M. C. Doherty, U. Lopatin, C. P. Johnston, G. Sinha, T. Ross, M. Cai, N. N. Hansel, T. Perl, J. R. Ticehurst, K. Carroll, D. L. Thomas, E. Nuermberger, and J. G. Bartlett. 2005. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin. Infect. Dis. 40:100-107.
16. Garnier, F., D. Chainier, T. Walsh, A. Karlsson, A. Bolmström, C. Grelaud, M. Mounier, F. Denis, and M. C. Ploy. 2006. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J. Antimicrob. Chemother. 57:146-149.
17. Gonzalez, B. E., K. G. Hulten, M. K. Dishop, L. B. Lamberth, W. A. Hammerman, E. O. Mason, Jr., and S. L. Kaplan. 2005. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus. Clin. Infect. Dis. 41:583-590.
18. Healy, C. M., K. G. Hulten, D. L. Palazzi, J. R. Campbell, and C. J. Baker. 2004. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin. Infect. Dis. 39:1460-1466.
19. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multi-functional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
20. Hongo, I., T. Baba, K. Oishi, Y. Morimoto, T. Ito, and K. Hiramatsu. 2009. Phenol-soluble modulin alpha 3 enhances the human neutrophil lysis mediated by Panton-Valentine leukocidin. J. Infect. Dis. 200:715-723.
21. Julian, K., K. Kosowska-Shick, C. Whitener, M. Roos, H. Labischinski, A. Rubio, L. Parent, L. Ednie, L. Koeth, T. Bogdanovich, and P. C. Appelbaum. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448.
22. Kazakova, S. V., J. C. Hageman, M. Matava, A. Srinivasan, L. Phelan, B. Garfinkel, T. Boo, S. McAllister, J. Anderson, B. Jensen, D. Dodson, D. Lonsway, L. K. McDougal, M. Arduino, V. J. Fraser, G. Killgore, F. C. Tenover, S. Cody, and D. B. Jernigan. 2005. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N. Engl. J. Med. 352:468-475.
23. Leuthner, K. D., C. M. Cheung, and M. J. Rybak. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:338-343.
24. Miller, L. G., F. Perdreau-Remington, G. Rieg, S. Mehdi, J. Perlroth, A. S. Bayer, A. W. Tang, T. O. Phung, and B. Spellberg. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352:1445-1453.
25. Rubinstein, E., G. R. Corey, M. E. Stryjewski, H. W. Boucher, R. N. Daly, F. C. Gentner, S. L. Barriere, M. M. Kitt, and H. D. Friedland. 2008. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies, abstr. O75. Abstr. 18th Eur. Congr. Clin. Microbiol. Infect. Dis. Wiley-Blackwell, Oxford, United Kingdom.
26. Stryjewski, M. E., D. R. Graham, S. E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D. P. Ross, V. G. Fowler, A. Hopkins, H. D. Friedland, S. L. Barriere, M. M. Kitt, and G. R. Corey on behalf of the Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46:1683-1693.
27. Stryjewski, M. E., V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallée, V. G. Fowler, Jr., J. Morganroth, S. L. Barriere, M. M. Kitt, G. R. Corey, and the FAST investigator group. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867.
28. Stryjewski, M. E., W. D. O'Riordan, W. K. Lau, F. D. Pien, L. M. Dunbar, M. Vallee, V. G. Fowler, Jr., V. C. Chu, E. Spencer, S. L. Barriere, M. M. Kitt, C. H. Cabell, G. R. Corey, and the FAST investigator group. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. 40:1601.
29. Takizawa, Y., I. Taneike, S. Nakagawa, T. Oishi, Y. Nitahara, N. Iwakura, K. Ozaki, M. Takano, T. Nakayama, and T. Yamamoto. 2005. A Panton-Valentine leukocidin (PVL)-positive community-acquired methicillin-resistant Staphylococcus aureus (MRSA) strain, another such strain carrying a multiple-drug resistance plasmid, and other more-typical PVL-negative MRSA strains found in Japan. Antimicrob. Agents Chemother. 43:3356-3363.
30. Tenover, F. C., L. K. McDougal, R. V. Goering, G. Killgore, S. J. Projan, J. B. Patel, and P. M. Dunman. 2006. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. Antimicrob. Agents Chemother. 44:108-118.
31. Tenover, F. C., L. M. Weigel, P. C. Appelbaum, L. K. McDougal, J. Chaitram, S. McAllister, N. Clark, G. Killgore, C. M. O'Hara, L. Jevitt, J. B. Patel, and B. Bozdogan. 2004. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob. Agents Chemother. 48:275-280.